Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 214Lymphoma 47Leukemia 46Multiple Myeloma 44Leukemia, Lymphocytic, Chronic, B-Cell 42Neoplasms, Plasma Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Monoclonal Gammopathy of Undetermined Significance 39Lymphoma, Non-Hodgkin 38Lymphoma, Mantle-Cell 37Lymphoma, Large-Cell, Immunoblastic 37Lymphoma, Large B-Cell, Diffuse 37Lymphoma, Follicular 37Myelodysplastic Syndromes 36Burkitt Lymphoma 36Lymphoma, B-Cell, Marginal Zone 35Leukemia, Myeloid, Acute 35Hodgkin Disease 35Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 34Myeloproliferative Disorders 34Immunoglobulin Light-chain Amyloidosis 33Waldenstrom Macroglobulinemia 32Immunoblastic Lymphadenopathy 32Uterine Cervical Neoplasms 31Lymphoma, Large-Cell, Anaplastic 31Primary Myelofibrosis 30Thrombocythemia, Essential 29Leukemia, Hairy Cell 29Leukemia, Biphenotypic, Acute 29Uterine Cervical Dysplasia 28

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Condition: Advanced Tumors × Other neoplasm × Clear all
NCT05650203 2023-04-05

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn
Other neoplasm

Primary Condition: Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡